ASH 2018 | Significantly improving HRQL and neurocognition in high-risk sickle cell following familial ASCT

Mitchell Cairo

Mitchell Cairo, MD, of New York Medical College, Valhalla, NY, discusses the NYMC-571 trial (NCT02675959). This showed significantly improved long-term health-related quality of life and neurocognition in high-risk sickle cell disease patients following familial haploidentical stem cell transplantation that used CD34-enriched and CD3 mononuclear addback. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video